HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer.

Hypoxia-inducible factors (HIFs) and the HIF-dependent cancer hallmarks angiogenesis and metabolic rewiring are well-established drivers of breast cancer aggressiveness, therapy resistance, and poor prognosis. Targeting of HIF and its downstream targets in angiogenesis and metabolism has been unsuccessful so far in the breast cancer clinical setting, with major unresolved challenges residing in target selection, development of robust biomarkers for response prediction, and understanding and harnessing escape mechanisms. This Review discusses the pathophysiological role of HIFs, angiogenesis, and metabolism in breast cancer and the challenges of targeting these features in breast cancer patients. Rational therapeutic combinations, especially with immunotherapy and endocrine therapy, seem most promising in the clinical exploitation of the intricate interplay of HIFs, angiogenesis, and metabolism in breast cancer cells and the tumor microenvironment.

[1]  H. Groen,et al.  Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study , 2021, Clinical Cancer Research.

[2]  D. Sabatini,et al.  Dietary modifications for enhanced cancer therapy , 2020, Nature.

[3]  Lingyun Zheng,et al.  Decylubiquinone suppresses breast cancer growth and metastasis by inhibiting angiogenesis via the ROS/p53/ BAI1 signaling pathway , 2020, Angiogenesis.

[4]  Gary D. Bader,et al.  A network analysis to identify mediators of germline-driven differences in breast cancer prognosis , 2020, Nature Communications.

[5]  M. Leach,et al.  Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration , 2020, British Journal of Cancer.

[6]  P. Fasching,et al.  A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial , 2020, Clinical Cancer Research.

[7]  R. Sweeney,et al.  Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes , 2020, Medical Oncology.

[8]  I. Nabi,et al.  Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 , 2020, Molecular Cancer Research.

[9]  Maohui Luo,et al.  HIF-2-induced long non-coding RNA RAB11B-AS1 promotes hypoxia-mediated angiogenesis and breast cancer metastasis. , 2020, Cancer research.

[10]  A. Harris.  Clinical strategies to inhibit tumor vascularization , 2020 .

[11]  S. O’Rahilly,et al.  GDF15 mediates the effects of metformin on body weight and energy balance , 2019, Nature.

[12]  Betty Y. S. Kim,et al.  Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade , 2019, Clinical Cancer Research.

[13]  H. Lee,et al.  A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells. , 2019, Cell metabolism.

[14]  R. Schiff,et al.  FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer , 2019, Proceedings of the National Academy of Sciences.

[15]  A. Ehinger,et al.  Expression of HIF-1α is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer , 2019, PloS one.

[16]  S. Samuel,et al.  Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer , 2019, Biomolecules.

[17]  Ahmedin Jemal,et al.  Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[18]  Daniele M. Gilkes,et al.  Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis , 2019, Nature Communications.

[19]  F. Mulero,et al.  Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer , 2019, Clinical Cancer Research.

[20]  William P. Katt,et al.  Liver-Type Glutaminase GLS2 Is a Druggable Metabolic Node in Luminal-Subtype Breast Cancer , 2019, Cell reports.

[21]  I. Grosse,et al.  Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism , 2019, International journal of molecular sciences.

[22]  E. Winer,et al.  A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases , 2019, Breast Cancer Research and Treatment.

[23]  S. Merajver,et al.  Breast cancers utilize hypoxic glycogen stores via PYGB, the brain isoform of glycogen phosphorylase, to promote metastatic phenotypes , 2019, PloS one.

[24]  Robin L. Jones,et al.  Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours , 2019, European journal of cancer.

[25]  C. Scapulatempo-Neto,et al.  CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy , 2019, BMC Cancer.

[26]  J. Xie,et al.  Hypoxia-reprogrammed tricarboxylic acid cycle promotes the growth of human breast tumorigenic cells , 2019, Oncogene.

[27]  S. Demo,et al.  Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer , 2019, Front. Oncol..

[28]  Satchidananda Panda,et al.  Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment. , 2019, Trends in cancer.

[29]  Pierre Sonveaux,et al.  Monocarboxylate transporters in cancer , 2019, Molecular metabolism.

[30]  Venkatram R. Mereddy,et al.  Development and radiosynthesis of the first 18 F-labeled inhibitor of monocarboxylate transporters (MCTs). , 2019, Journal of labelled compounds & radiopharmaceuticals.

[31]  Peijun Liu,et al.  Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation , 2019, Journal of experimental & clinical cancer research : CR.

[32]  S. Sivanand,et al.  Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting. , 2019, Cell metabolism.

[33]  C. Supuran,et al.  A non-catalytic function of carbonic anhydrase IX contributes to the glycolytic phenotype and pH regulation in human breast cancer cells. , 2019, The Biochemical journal.

[34]  R. Colomer,et al.  Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition , 2019, Breast Cancer Research.

[35]  S. C. Chafe,et al.  Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically , 2019, Cancer Immunology Research.

[36]  Isaac Daimiel.  Insights into Hypoxia: Non-invasive Assessment through Imaging Modalities and Its Application in Breast Cancer , 2019, Journal of breast cancer.

[37]  R. McKenna,et al.  CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells , 2019, bioRxiv.

[38]  F. Su,et al.  Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells , 2019, Nature Cell Biology.

[39]  G. Mills,et al.  Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy , 2019, Nature Metabolism.

[40]  Yan Guo,et al.  Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer , 2019, Nature Communications.

[41]  Quan Chen,et al.  The SIAH2-NRF1 axis spatially regulates tumor microenvironment remodeling for tumor progression , 2019, Nature Communications.

[42]  Weifeng Hong,et al.  Prognostic role of glycolysis for cancer outcome: evidence from 86 studies , 2019, Journal of Cancer Research and Clinical Oncology.

[43]  R. Jain,et al.  Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges. , 2019, Annual review of physiology.

[44]  E. Boedtkjer.  Na+,HCO3− cotransporter NBCn1 accelerates breast carcinogenesis , 2019, Cancer and Metastasis Reviews.

[45]  C. Ward,et al.  HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer , 2019, Breast Cancer Research.

[46]  D. Dorsch,et al.  Ablation of the ASCT2 (SLC1A5) gene encoding a neutral amino acid transporter reveals transporter plasticity and redundancy in cancer cells , 2019, The Journal of Biological Chemistry.

[47]  R. Kerbel,et al.  Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer , 2019, Journal of experimental & clinical cancer research : CR.

[48]  M. Ashcroft,et al.  CHCHD4 confers metabolic vulnerabilities to tumour cells through its control of the mitochondrial respiratory chain , 2019, Cancer & Metabolism.

[49]  Xingli Wu,et al.  The prognostic value of hypoxia-inducible factor-1α in advanced cancer survivors: a meta-analysis with trial sequential analysis , 2019, Therapeutic advances in medical oncology.

[50]  M. de Ridder,et al.  Hypoxic Radioresistance: Can ROS Be the Key to Overcome It? , 2019, Cancers.

[51]  L. Farahmand,et al.  Challenges facing antiangiogenesis therapy: The significant role of hypoxia‐inducible factor and MET in development of resistance to anti‐vascular endothelial growth factor‐targeted therapies , 2018, Journal of cellular physiology.

[52]  P. Ratcliffe,et al.  Inherent DNA‐binding specificities of the HIF‐1α and HIF‐2α transcription factors in chromatin , 2018, EMBO reports.

[53]  A. Harris,et al.  Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer , 2019, Proceedings of the National Academy of Sciences.

[54]  G. Semenza,et al.  Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy. , 2019, Advances in cancer research.

[55]  D. Lin,et al.  The Clinicopathologic and Prognostic Value of Hypoxia-Inducible Factor-2α in Cancer Patients: A Systematic Review and Meta-Analysis , 2018, Cancer Epidemiology, Biomarkers & Prevention.

[56]  Honglin Hou,et al.  Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer , 2018, Medicine.

[57]  H. Lane,et al.  Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells , 2018, Cell reports.

[58]  V. Jendrossek,et al.  Targeting SLC25A10 alleviates improved antioxidant capacity and associated radioresistance of cancer cells induced by chronic-cycling hypoxia. , 2018, Cancer letters.

[59]  Nicholas L. Bormann,et al.  Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4 , 2018, Oncogene.

[60]  Fergus Gleeson,et al.  Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer , 2018, Cell metabolism.

[61]  Andrew N Lane,et al.  Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance , 2018, Nature Communications.

[62]  A. Dutt,et al.  Up-regulation of the kinase gene SGK1 by progesterone activates the AP-1–NDRG1 axis in both PR-positive and -negative breast cancer cells , 2018, The Journal of Biological Chemistry.

[63]  V. Longo,et al.  Fasting and cancer: molecular mechanisms and clinical application , 2018, Nature Reviews Cancer.

[64]  Jie Li,et al.  Diffuse optical spectroscopy for monitoring the responses of patients with breast cancer to neoadjuvant chemotherapy , 2018, Medicine.

[65]  A. Giobbie-Hurder,et al.  BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation , 2018, Proceedings of the National Academy of Sciences.

[66]  J. Satagopan,et al.  LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response , 2018, PloS one.

[67]  Florence T. H. Wu,et al.  Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease , 2018, British Journal of Cancer.

[68]  B. Gower,et al.  A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer. , 2018, The Journal of nutrition.

[69]  G. Semenza,et al.  Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[70]  M. Dimopoulos,et al.  Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial , 2018, PloS one.

[71]  T. Hasebe,et al.  Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer , 2018, Breast Cancer Research.

[72]  E. Fertig,et al.  Molecular Portrait of Hypoxia in Breast Cancer: A Prognostic Signature and Novel HIF-Regulated Genes , 2018, Molecular Cancer Research.

[73]  E. Rozeman,et al.  Targeting tumor-associated acidity in cancer immunotherapy , 2018, Cancer Immunology, Immunotherapy.

[74]  M. Hallek,et al.  Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer , 2018, Oncogene.

[75]  Alexandre Cochet,et al.  Breast Cancer Blood Flow and Metabolism on Dual-Acquisition 18F-FDG PET: Correlation with Tumor Phenotype and Neoadjuvant Chemotherapy Response , 2018, The Journal of Nuclear Medicine.

[76]  L. Quek,et al.  Benzylserine inhibits breast cancer cell growth by disrupting intracellular amino acid homeostasis and triggering amino acid response pathways , 2018, BMC Cancer.

[77]  Robert J. Griffin,et al.  Consensus guidelines for the use and interpretation of angiogenesis assays , 2018, Angiogenesis.

[78]  S. Pastoreková,et al.  The proteoglycan-like domain of carbonic anhydrase IX mediates non-catalytic facilitation of lactate transport in cancer cells , 2018, Oncotarget.

[79]  Christopher J. Sevinsky,et al.  NDRG1 regulates neutral lipid metabolism in breast cancer cells , 2018, Breast Cancer Research.

[80]  W. Luo,et al.  ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis , 2018, The Journal of clinical investigation.

[81]  M. Antoniewicz.  A guide to 13C metabolic flux analysis for the cancer biologist , 2018, Experimental & Molecular Medicine.

[82]  I. Ellis,et al.  The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours , 2018, Breast Cancer Research.

[83]  R. Jain,et al.  Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2 , 2018, Science Translational Medicine.

[84]  R. Greil,et al.  DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer , 2018, Theranostics.

[85]  King-Jen Chang,et al.  Metformin-induced caveolin-1 expression promotes T-DM1 drug efficacy in breast cancer cells , 2018, Scientific Reports.

[86]  B. Krishnamachary,et al.  Metabolic consequences of HIF silencing in a triple negative human breast cancer xenograft , 2018, Oncotarget.

[87]  R. Kerbel,et al.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa , 2018, Nature Reviews Clinical Oncology.

[88]  G. MacGregor,et al.  Glucose-dependent growth arrest of leukemia cells by MCT1 inhibition: Feeding Warburg's sweet tooth and blocking acid export as an anticancer strategy. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[89]  Huichun Liang,et al.  Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis , 2018, Oncogene.

[90]  J. Gehl,et al.  Molecular Mechanisms Linking Exercise to Cancer Prevention and Treatment. , 2018, Cell metabolism.

[91]  Joe T. Sharick,et al.  Pharmacological Blockade of ASCT2-dependent Glutamine Transport Leads To Anti-tumor Efficacy in Preclinical Models , 2017, Nature Medicine.

[92]  A. Harris,et al.  Advances in Hypoxia-Inducible Factor Biology. , 2017, Cell metabolism.

[93]  J. Bergh,et al.  An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression , 2017, Cancer cell.

[94]  D. Urban,et al.  Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). , 2017, Journal of medicinal chemistry.

[95]  David C. Smith,et al.  Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours , 2017 .

[96]  S. Fesik,et al.  MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. , 2017, Cell metabolism.

[97]  D. Wiederschain,et al.  Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition , 2017, PloS one.

[98]  N. Netzer,et al.  The Linkage between Breast Cancer, Hypoxia, and Adipose Tissue , 2017, Front. Oncol..

[99]  S. Fox,et al.  Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer , 2017, Oncotarget.

[100]  S. Rey,et al.  Hypoxic pathobiology of breast cancer metastasis. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[101]  T. Yamane,et al.  Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis , 2017, Clinical Cancer Research.

[102]  A. Harris,et al.  In vitro downregulated hypoxia transcriptome is associated with poor prognosis in breast cancer , 2017, Molecular Cancer.

[103]  S. Aparicio,et al.  Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab) , 2017, Breast Cancer Research and Treatment.

[104]  Z. Jia,et al.  The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review , 2017, European Radiology.

[105]  Yu Zhou,et al.  The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis , 2017, Oncotarget.

[106]  D. Hanahan,et al.  Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation , 2017, Science Translational Medicine.

[107]  Y. Kienast,et al.  Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade , 2017, Science Translational Medicine.

[108]  F. Stossi,et al.  Mutual Regulation of Tumour Vessel Normalization and Immunostimulatory Reprogramming , 2017, Nature.

[109]  J. Griffiths,et al.  The action of β-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β-hydroxybutyrate paradox , 2017, Cancer & metabolism.

[110]  G. Semenza.  Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype , 2017, The EMBO journal.

[111]  E. Winer,et al.  Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients , 2016, The oncologist.

[112]  R. Wenger,et al.  Correction: Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2α in invasive breast cancer cells , 2016, OncoTarget.

[113]  D. Miles,et al.  Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. , 2017, European journal of cancer.

[114]  Zhiqiao Zhang,et al.  Prognostic Significance of High VEGF-C Expression for Patients with Breast Cancer: An Update Meta Analysis , 2016, PloS one.

[115]  G. G. Van den Eynden,et al.  Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases , 2016, Nature Medicine.

[116]  B. Pogue,et al.  Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. , 2016, Cancer research.

[117]  A. Schulze,et al.  The multifaceted roles of fatty acid synthesis in cancer , 2016, Nature Reviews Cancer.

[118]  F. Wang,et al.  Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis. , 2016, Breast.

[119]  G. Semenza,et al.  PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis. , 2016, Cancer research.

[120]  S. Påhlman,et al.  Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.

[121]  Gordon C Jayson,et al.  Antiangiogenic therapy in oncology: current status and future directions , 2016, The Lancet.

[122]  Chi V. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[123]  A. Harris,et al.  Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment , 2016, EBioMedicine.

[124]  R. Liddington,et al.  Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1α Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. , 2016, Cancer research.

[125]  A. Richardson,et al.  Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine , 2016, Cell.

[126]  A. Msaki,et al.  A hypoxic signature marks tumors formed by disseminated tumor cells in the BALB-neuT mammary cancer model , 2016, Oncotarget.

[127]  R. Wenger,et al.  Estrogen-dependent downregulation of hypoxia-inducible factor (HIF)-2α in invasive breast cancer cells , 2016, Oncotarget.

[128]  W. Oyen,et al.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  P. Lambin,et al.  Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis , 2016, Front. Oncol..

[130]  R. Wenger,et al.  ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models , 2016, Molecular Cancer.

[131]  G. Semenza,et al.  The hypoxic tumor microenvironment: A driving force for breast cancer progression. , 2016, Biochimica et biophysica acta.

[132]  S. Horvath,et al.  MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. , 2016, Cell reports.

[133]  W. Ritchie,et al.  ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer , 2015, Oncogene.

[134]  P. Nunn,et al.  The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor , 2015, Brain pathology.

[135]  Xi Chen,et al.  EglN2 associates with the NRF1‐PGC1α complex and controls mitochondrial function in breast cancer , 2015, The EMBO journal.

[136]  J. Ragoussis,et al.  Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer , 2015, Proceedings of the National Academy of Sciences.

[137]  H. Putter,et al.  The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study , 2015, BMC Cancer.

[138]  R. McKenna,et al.  Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function , 2015, Scientific Reports.

[139]  Z. Shao,et al.  Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer , 2015, Journal of Experimental & Clinical Cancer Research.

[140]  G. Semenza,et al.  Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype , 2015, Proceedings of the National Academy of Sciences.

[141]  Kai Li,et al.  Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases , 2015, Diagnostic Pathology.

[142]  H. Wildiers,et al.  Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. , 2015, Breast.

[143]  Shiuan Chen,et al.  Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[144]  J. Mackey,et al.  A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors , 2015, Investigational New Drugs.

[145]  Jeffrey W. Smith,et al.  Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. , 2015, Cancer cell.

[146]  Jian-Ting Zhang,et al.  Repositioning Proton Pump Inhibitors as Anticancer Drugs by Targeting the Thioesterase Domain of Human Fatty Acid Synthase , 2014, Journal of medicinal chemistry.

[147]  Thomas Bachelot,et al.  Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. , 2014, The Lancet. Oncology.

[148]  G. Semenza,et al.  Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells , 2014, Proceedings of the National Academy of Sciences.

[149]  A. Blackburn,et al.  Targeting of two aspects of metabolism in breast cancer treatment , 2014, Cancer biology & therapy.

[150]  H. Kolb,et al.  The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. , 2014, Antioxidants & redox signaling.

[151]  Zhandong Liu,et al.  Serine catabolism regulates mitochondrial redox control during hypoxia. , 2014, Cancer discovery.

[152]  G. Semenza,et al.  Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis , 2014, Proceedings of the National Academy of Sciences.

[153]  G. Pond,et al.  Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[154]  M. Weller,et al.  ERGO: A pilot study of ketogenic diet in recurrent glioblastoma , 2014, International journal of oncology.

[155]  A. Harris,et al.  Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy , 2014, British Journal of Cancer.

[156]  M. Ferrari,et al.  XBP1 Promotes Triple Negative Breast Cancer By Controlling the HIF1 α Pathway , 2014, Nature.

[157]  P. V. van Diest,et al.  The potential of hypoxia markers as target for breast molecular imaging – a systematic review and meta-analysis of human marker expression , 2013, BMC Cancer.

[158]  Eileen Holmes,et al.  18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO , 2013, The Journal of Nuclear Medicine.

[159]  G. Semenza,et al.  HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. , 2013, The Journal of clinical investigation.

[160]  A. Lánczky,et al.  A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer , 2013, Breast Cancer Research and Treatment.

[161]  P. Ratcliffe,et al.  Pan-genomic binding of hypoxia-inducible transcription factors , 2013, Biological chemistry.

[162]  M. S. Mcmurtry,et al.  Mitochondrial activation by inhibition of PDKII suppresses HIF1a signaling and angiogenesis in cancer , 2013, Oncogene.

[163]  Guangyu Liu,et al.  18F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer , 2013, The Journal of Nuclear Medicine.

[164]  P. V. van Diest,et al.  HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers , 2013, PloS one.

[165]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[166]  M. Zucchetti,et al.  The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts , 2012, Molecular Cancer Therapeutics.

[167]  M. Malumbres,et al.  HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5. , 2012, Molecular cell.

[168]  R. Deberardinis,et al.  Metabolism of [U‐13C]glucose in human brain tumors in vivo , 2012, NMR in biomedicine.

[169]  Junjeong Choi,et al.  Metabolism-Related Proteins Are Differentially Expressed according to the Molecular Subtype of Invasive Breast Cancer Defined by Surrogate Immunohistochemistry , 2012, Pathobiology.

[170]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[171]  A. Harris,et al.  Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression. , 2012, The Journal of clinical investigation.

[172]  G. Semenza,et al.  HIF-1-dependent Expression of Angiopoietin-like 4 and L1CAM Mediates Vascular Metastasis of Hypoxic Breast Cancer Cells to the Lungs , 2011, Oncogene.

[173]  Robert J Gillies,et al.  Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes , 2011, Clinical Cancer Research.

[174]  C. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[175]  F. Shibasaki,et al.  Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells. , 2011, Archives of biochemistry and biophysics.

[176]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[177]  Chi V. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[178]  E. Mayer,et al.  Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies , 2010, Clinical Cancer Research.

[179]  Hans Christian Pedersen,et al.  Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy , 2010, Breast Cancer Research.

[180]  H. Iwata,et al.  Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer , 2010, Breast Cancer Research and Treatment.

[181]  S. Fox,et al.  Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[182]  Linda Holmquist Mengelbier,et al.  Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. , 2008, Cancer research.

[183]  B. Potter,et al.  2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer , 2008, British Journal of Cancer.

[184]  E. Shpall,et al.  Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy , 2007, British Journal of Cancer.

[185]  P. Bonnier,et al.  Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. , 2007, Human pathology.

[186]  Manuela Milani,et al.  Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.

[187]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[188]  Manuela Milani,et al.  Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[189]  E. van Marck,et al.  Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer , 2005, British Journal of Cancer.

[190]  E. Stanbridge,et al.  Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. , 2005, Cancer research.

[191]  A. Harris,et al.  c-erbB-2 Related Aggressiveness in Breast Cancer Is Hypoxia Inducible Factor-1α Dependent , 2004, Clinical Cancer Research.

[192]  Patrick Nicolas,et al.  Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. , 2004, Cancer research.

[193]  E. van Marck,et al.  Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia , 2004, British Journal of Cancer.

[194]  A. Harris,et al.  c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[195]  P. V. van Diest,et al.  Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma , 2003, Cancer.

[196]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[197]  A. Harris,et al.  Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[198]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[199]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[200]  W. Sly,et al.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. , 2001, The American journal of pathology.

[201]  G. Semenza,et al.  Levels of Hypoxia-Inducible Factor-1α During Breast Carcinogenesis , 2001 .

[202]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[203]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .

[204]  M. Gassmann,et al.  Oxygen-regulated Transferrin Expression Is Mediated by Hypoxia-inducible Factor-1* , 1997, The Journal of Biological Chemistry.

[205]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[206]  R. Kettmann,et al.  Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. , 1994, Oncogene.

[207]  P Vaupel,et al.  Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. , 1991, Cancer research.

[208]  J. Kwiatkowski,et al.  Lipogenetic and glycolytic enzyme activities in carcinoma and nonmalignant diseases of the human breast. , 1979, British Journal of Cancer.